header mobile logo

IPSEN CARES PATIENT SUPPORT
PROGRAM OFFERINGS

IPSEN CARES PATIENT
SUPPORT PROGRAM
OFFERINGS

ipsen-cares-logo-01

Resources to support your patients’ access to TAZVERIK®

icon-support-assistance

Patient Assistance
Program (PAP)

Patients may be eligible to receive a limited supply of free medication if they are uninsured or underinsured (based on program eligibility criteria).

Bridge Supply Program

Bridge Supply Program

Helping existing commercial patients access medication should they experience change or delay in drug coverage.

icon-support-assistance

Patient Assistance Program 
(PAP)

Patients may be eligible to receive a limited supply of free medication if they are uninsured or underinsured (based on program eligibility criteria).

Patients may be eligible to receive
a limited supply of free medication
if they are uninsured or underinsured
(based on program eligibility criteria).

Quick-start-program-icon

Quick Start Program

New commercial patients may be eligible to receive a limited supply of free medication.

New commercial patients may
be eligible to receive a limited
supply of free medication.

icon-support-bottle-pill

Quick Start Program

New commercial patients may be eligible to receive a limited supply of free medication.

icon-support-bridge

Co-Pay Assistance Program

Patients with commercial health insurance may be eligible to receive co-payment assistance from Ipsen to help reduce out-of-pocket costs for TAZVERIK.*

Bridge Supply Program

Bridge Supply Program

Helping existing commercial patients access medication should they experience change or delay in drug coverage.

Helping existing commercial
patients access medication should
they experience change or delay
in drug coverage.

icon-support-bridge

Co-Pay Assistance Program

Patients with commercial health insurance may be eligible to receive co-payment assistance from Ipsen to help reduce out-of-pocket costs for TAZVERIK.*

Patients with commercial health   
insurance may be eligible to receive   
co-payment assistance from Ipsen   
to help reduce out-of-pocket   
costs for TAZVERIK.*

Are you a healthcare professional or pharmacy looking to enroll your patient in the Ipsen Cares Co-Pay Assistance Program?

Your commercially insured patients may be eligible to receive co-pay assistance. Note that only patients’ prescribers and specialty pharmacies can register patients for this program.

Your commercially insured patients may 
be eligible to receive co-pay 
assistance. Note that only patients’ 
prescribers and specialty 
pharmacies can register patients for this 
program.

FOR HEALTHCARE PROFESSIONALS ONLY

 

Note: All patient support is subject to eligibility criteria and program terms and conditions.

This offer is not valid for cash-paying patients or patients currently enrolled in Medicare, Medicaid, or any other federal or state or healthcare program. Limitations apply. Void where prohibited.

 

ipsen-cares-logo-01

If you are interested in learning more about any of the support offerings mentioned, including eligibility requirements, visit ipsencares.com or contact Ipsen Cares at 1-866-435-5677, Monday through Friday, (8 AM – 8 PM ET).

IMPORTANT SAFETY INFORMATION AND INDICATIONS

  • Secondary Malignancies

The risk of developing secondary malignancies is increased following treatment with TAZVERIK. Across clinical trials of 758 adults who received TAZVERIK 800 mg twice daily as monotherapy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or B-cell acute lymphoblastic leukemia (B-ALL) occurred in 1.7% of patients. One pediatric patient developed T-cell lymphoblastic lymphoma (T-LBL). Monitor patients long-term for the development of secondary malignancies.

  • Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure (area under the plasma concentration time curve [AUC0-45h]) at the 800 mg twice daily dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAZVERIK and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose.

Adverse Reactions

In 99 clinical study patients with relapsed or refractory follicular lymphoma receiving TAZVERIK 800 mg twice daily: Serious adverse reactions occurred in 30% of patients who received TAZVERIK. Serious adverse reactions occurring in ≥2% were general physical health deterioration, abdominal pain, pneumonia, sepsis, and anemia. The most common (≥20%) adverse reactions were fatigue (36%), upper respiratory tract infection (30%), musculoskeletal pain (22%), nausea (24%), and abdominal pain (20%).

Drug Interactions

Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose.

Avoid coadministration of moderate or strong CYP3A inducers with TAZVERIK, which may decrease the efficacy of TAZVERIK.

Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates.

Lactation

Because of the potential risk for serious adverse reactions from TAZVERIK in the breastfed child, advise women not to breastfeed during treatment with TAZVERIK and for one week after the final dose.

To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS

TAZVERIK is indicated for the treatment of:

  • Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.
  • Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Please see full 
Prescribing Information.